Cargando…
Clinical analysis and prognostic significance of hepatitis B virus infections for diffuse large B-cell lymphoma with or without rituximab therapy
The aim of this study was to analyze the clinical features of hepatitis B surface antigen (HBsAg)-positive and negative diffuse large B-cell lymphomas (DLBCLs) and to compare the outcomes and serum hepatitis B virus (HBV)-DNA loads of patients treated with cyclophosphamide, doxorubicin, vincristine...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3735511/ https://www.ncbi.nlm.nih.gov/pubmed/23935730 http://dx.doi.org/10.3892/etm.2013.1079 |
_version_ | 1782279658697392128 |
---|---|
author | XIE, WANZHUO ZHOU, DE HU, KEYUE XIAO, XIBIN HUANG, WEIJIA HE, JINSONG SHI, JIMIN LUO, YI ZHANG, JIE LIN, MAOFANG CAI, ZHEN HUANG, HE YE, XIUJIN |
author_facet | XIE, WANZHUO ZHOU, DE HU, KEYUE XIAO, XIBIN HUANG, WEIJIA HE, JINSONG SHI, JIMIN LUO, YI ZHANG, JIE LIN, MAOFANG CAI, ZHEN HUANG, HE YE, XIUJIN |
author_sort | XIE, WANZHUO |
collection | PubMed |
description | The aim of this study was to analyze the clinical features of hepatitis B surface antigen (HBsAg)-positive and negative diffuse large B-cell lymphomas (DLBCLs) and to compare the outcomes and serum hepatitis B virus (HBV)-DNA loads of patients treated with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) regimens with rituximab (RCHOP) or without. A total of 451 DLBCL patients, of which 90 were HBsAg-positive and 361 were HBsAg-negative, were retrospectively reviewed. We compared onset age, gender, Ann Arbor stage, international prognostic index (IPI), lactate dehydrogenase (LDH) and β2-microglobulin (β2-M) levels, as well as overall survival (OS) rates and HBV-DNA loads under CHOP or RCHOP regimens. The OS rate of the HBsAg-positive DLBCL patients was significantly lower than that of HBsAg-negative DLBCL patients and the HBsAg-positive DLBCL patients had an earlier median onset age. HBsAg-positive DLBCL patients had poorer OS rates compared with HBsAg-negative patients (62.2% HBsAg-positive vs. 76.2% HBsAg-negative, P=0.018). HBsAg-positive DLBCL patients with HBV-DNA loads >10(3) cps/ml during chemotherapy had significantly lower OS rates than those with lower HBV-DNA loads (48.4% HBV-DNA elevated vs. 71.2% HBV-DNA normal, P=0.037). HBsAg-positive DLBCL patients treated with RCHOP had a significantly higher OS rate (79.6%) compared with the 41 CHOP-treated patients (43.9%; P<0.001). HBsAg-positive DLBCL patients with an earlier median onset age and elevated HBV-DNA during chemotherapy had poorer prognoses. HBsAg and HBV-DNA during chemotherapy may be used as prognostic indicators for patients with DLBCL. Rituximab improves the outcome of HBsAg-positive DLBCL patients when administered in combination with anti-viral lamivudine. |
format | Online Article Text |
id | pubmed-3735511 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-37355112013-08-09 Clinical analysis and prognostic significance of hepatitis B virus infections for diffuse large B-cell lymphoma with or without rituximab therapy XIE, WANZHUO ZHOU, DE HU, KEYUE XIAO, XIBIN HUANG, WEIJIA HE, JINSONG SHI, JIMIN LUO, YI ZHANG, JIE LIN, MAOFANG CAI, ZHEN HUANG, HE YE, XIUJIN Exp Ther Med Articles The aim of this study was to analyze the clinical features of hepatitis B surface antigen (HBsAg)-positive and negative diffuse large B-cell lymphomas (DLBCLs) and to compare the outcomes and serum hepatitis B virus (HBV)-DNA loads of patients treated with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) regimens with rituximab (RCHOP) or without. A total of 451 DLBCL patients, of which 90 were HBsAg-positive and 361 were HBsAg-negative, were retrospectively reviewed. We compared onset age, gender, Ann Arbor stage, international prognostic index (IPI), lactate dehydrogenase (LDH) and β2-microglobulin (β2-M) levels, as well as overall survival (OS) rates and HBV-DNA loads under CHOP or RCHOP regimens. The OS rate of the HBsAg-positive DLBCL patients was significantly lower than that of HBsAg-negative DLBCL patients and the HBsAg-positive DLBCL patients had an earlier median onset age. HBsAg-positive DLBCL patients had poorer OS rates compared with HBsAg-negative patients (62.2% HBsAg-positive vs. 76.2% HBsAg-negative, P=0.018). HBsAg-positive DLBCL patients with HBV-DNA loads >10(3) cps/ml during chemotherapy had significantly lower OS rates than those with lower HBV-DNA loads (48.4% HBV-DNA elevated vs. 71.2% HBV-DNA normal, P=0.037). HBsAg-positive DLBCL patients treated with RCHOP had a significantly higher OS rate (79.6%) compared with the 41 CHOP-treated patients (43.9%; P<0.001). HBsAg-positive DLBCL patients with an earlier median onset age and elevated HBV-DNA during chemotherapy had poorer prognoses. HBsAg and HBV-DNA during chemotherapy may be used as prognostic indicators for patients with DLBCL. Rituximab improves the outcome of HBsAg-positive DLBCL patients when administered in combination with anti-viral lamivudine. D.A. Spandidos 2013-07 2013-04-25 /pmc/articles/PMC3735511/ /pubmed/23935730 http://dx.doi.org/10.3892/etm.2013.1079 Text en Copyright © 2013, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
spellingShingle | Articles XIE, WANZHUO ZHOU, DE HU, KEYUE XIAO, XIBIN HUANG, WEIJIA HE, JINSONG SHI, JIMIN LUO, YI ZHANG, JIE LIN, MAOFANG CAI, ZHEN HUANG, HE YE, XIUJIN Clinical analysis and prognostic significance of hepatitis B virus infections for diffuse large B-cell lymphoma with or without rituximab therapy |
title | Clinical analysis and prognostic significance of hepatitis B virus infections for diffuse large B-cell lymphoma with or without rituximab therapy |
title_full | Clinical analysis and prognostic significance of hepatitis B virus infections for diffuse large B-cell lymphoma with or without rituximab therapy |
title_fullStr | Clinical analysis and prognostic significance of hepatitis B virus infections for diffuse large B-cell lymphoma with or without rituximab therapy |
title_full_unstemmed | Clinical analysis and prognostic significance of hepatitis B virus infections for diffuse large B-cell lymphoma with or without rituximab therapy |
title_short | Clinical analysis and prognostic significance of hepatitis B virus infections for diffuse large B-cell lymphoma with or without rituximab therapy |
title_sort | clinical analysis and prognostic significance of hepatitis b virus infections for diffuse large b-cell lymphoma with or without rituximab therapy |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3735511/ https://www.ncbi.nlm.nih.gov/pubmed/23935730 http://dx.doi.org/10.3892/etm.2013.1079 |
work_keys_str_mv | AT xiewanzhuo clinicalanalysisandprognosticsignificanceofhepatitisbvirusinfectionsfordiffuselargebcelllymphomawithorwithoutrituximabtherapy AT zhoude clinicalanalysisandprognosticsignificanceofhepatitisbvirusinfectionsfordiffuselargebcelllymphomawithorwithoutrituximabtherapy AT hukeyue clinicalanalysisandprognosticsignificanceofhepatitisbvirusinfectionsfordiffuselargebcelllymphomawithorwithoutrituximabtherapy AT xiaoxibin clinicalanalysisandprognosticsignificanceofhepatitisbvirusinfectionsfordiffuselargebcelllymphomawithorwithoutrituximabtherapy AT huangweijia clinicalanalysisandprognosticsignificanceofhepatitisbvirusinfectionsfordiffuselargebcelllymphomawithorwithoutrituximabtherapy AT hejinsong clinicalanalysisandprognosticsignificanceofhepatitisbvirusinfectionsfordiffuselargebcelllymphomawithorwithoutrituximabtherapy AT shijimin clinicalanalysisandprognosticsignificanceofhepatitisbvirusinfectionsfordiffuselargebcelllymphomawithorwithoutrituximabtherapy AT luoyi clinicalanalysisandprognosticsignificanceofhepatitisbvirusinfectionsfordiffuselargebcelllymphomawithorwithoutrituximabtherapy AT zhangjie clinicalanalysisandprognosticsignificanceofhepatitisbvirusinfectionsfordiffuselargebcelllymphomawithorwithoutrituximabtherapy AT linmaofang clinicalanalysisandprognosticsignificanceofhepatitisbvirusinfectionsfordiffuselargebcelllymphomawithorwithoutrituximabtherapy AT caizhen clinicalanalysisandprognosticsignificanceofhepatitisbvirusinfectionsfordiffuselargebcelllymphomawithorwithoutrituximabtherapy AT huanghe clinicalanalysisandprognosticsignificanceofhepatitisbvirusinfectionsfordiffuselargebcelllymphomawithorwithoutrituximabtherapy AT yexiujin clinicalanalysisandprognosticsignificanceofhepatitisbvirusinfectionsfordiffuselargebcelllymphomawithorwithoutrituximabtherapy |